HMR-1883, A NOVEL CARDIOSELECTIVE INHIBITOR OF THE ATP-SENSITIVE POTASSIUM CHANNEL - PART II - EFFECTS ON SUSCEPTIBILITY TO VENTRICULAR-FIBRILLATION INDUCED BY MYOCARDIAL-ISCHEMIA IN CONSCIOUS DOGS
Ge. Billman et al., HMR-1883, A NOVEL CARDIOSELECTIVE INHIBITOR OF THE ATP-SENSITIVE POTASSIUM CHANNEL - PART II - EFFECTS ON SUSCEPTIBILITY TO VENTRICULAR-FIBRILLATION INDUCED BY MYOCARDIAL-ISCHEMIA IN CONSCIOUS DOGS, The Journal of pharmacology and experimental therapeutics, 286(3), 1998, pp. 1465-1473
The activation of the ATP-sensitive potassium channel (K-ATP) during m
yocardial ischemia leads to potassium efflux, reductions in action pot
ential duration and the formation of ventricular fibrillation (VF). Dr
ugs that inactivate K-ATP should prevent these changes and thereby pre
vent VF. However, most K-ATP antagonists also alter pancreatic channel
s, which promote insulin release and hypoglycemia. Recently, a cardios
elective K-ATP antagonist, HMR 1883, has been developed that may offer
cardioprotection without the untoward side effects of existing compou
nds. Therefore, VF was induced in 13 mongrel dogs with healed myocardi
al infarctions by a 2-min coronary artery occlusion during the last mi
nute of a submaximal exercise test. On subsequent days, the exercise-p
lus-ischemia test was repeated after pretreatment with HMR 1883 (3.0 m
g/kg i.v., n = 13) or glibenclamide (1.0 mg/kg i.v., n = 7). HMR 1883
(P < .001) and glibenclamide (P < .01) prevented VF in 11 of 13 and 6
of 7 animals, respectively. Glibenclamide, but not HMR 1883, elicited
increases in plasma insulin and reductions in blood glucose. Glibencla
mide also reduced (P < .01) both mean coronary blood flow and left ven
tricular dP/dt maximum as well as the reactive hyperemia induced by 15
-sec coronary occlusions (-30.3 +/- 11%), whereas HMR 1883 did not alt
er this increase in coronary flow (-3.0 +/- 4.7%). Finally, myocardia[
ischemia (n = 10) significantly (P < .01) reduced refractory period (
control, 121 +/- 2 msec; occlusion, 115 +/- 2 msec), which was prevent
ed by either glibenclamide or HMR 1883. Thus, the cardioselective K-AT
P antagonist HMR 1883 can prevent ischemically induced reductions in r
efractory period and VF without major hemodynamic effects or alteratio
ns in blood glucose levels. These data further suggest that the activa
tion of K(ATP)s may play a particularly important role in both the red
uctions in refractory period and lethal arrhythmia formation associate
d with myocardial ischemia.